MedTrace Logo

Anti-Xa Level With Thromboprophylactic Dosage Nadroparin in Critically Ill COVID-19 and Non-COVID-19 Patients

NCT05926518 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 62

Last updated 2023-07-03

No results posted yet for this study

Summary

Primary objective The objective of this study is to compare anti-Xa levels obtained with a standard high dose thrombosis prophylaxis in COVID-19 intensive care-patients compared with anti-Xa levels obtained with a normal dose thrombosis prophylaxis in non-COVID-19 intensive care patients.

Secondary objectives

1. To determine the incidence of anti Xa levels out of range of the established target anti Xa level in both groups.
2. To determine the influence of relevant co-variates on the anti-Xa level in the COVID-19 and non-COVID-19 group.

Conditions

  • Critical Illness
  • Therapeutic Drug Monitoring
  • Venous Thromboembolism

Interventions

PROCEDURE

blood sampling

Blood sampling for the determination of anti-Xa peak levels 4 hours after administration of nadroparin sc.

Sponsors & Collaborators

  • Rijnstate Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2022-04-01
Completion
2022-11-23

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05926518 on ClinicalTrials.gov